214 related articles for article (PubMed ID: 17497736)
1. A comparative study of the antigen-specific immune response induced by co-delivery of CpG ODN and antigen using fusion molecules or biodegradable microparticles.
Zhang XQ; Dahle CE; Weiner GJ; Salem AK
J Pharm Sci; 2007 Dec; 96(12):3283-92. PubMed ID: 17497736
[TBL] [Abstract][Full Text] [Related]
2. Potent antigen-specific immune responses stimulated by codelivery of CpG ODN and antigens in degradable microparticles.
Zhang XQ; Dahle CE; Baman NK; Rich N; Weiner GJ; Salem AK
J Immunother; 2007; 30(5):469-78. PubMed ID: 17589287
[TBL] [Abstract][Full Text] [Related]
3. Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology.
San Román B; Irache JM; Gómez S; Tsapis N; Gamazo C; Espuelas MS
Eur J Pharm Biopharm; 2008 Sep; 70(1):98-108. PubMed ID: 18501572
[TBL] [Abstract][Full Text] [Related]
4. Diaminosulfide based polymer microparticles as cancer vaccine delivery systems.
Geary SM; Hu Q; Joshi VB; Bowden NB; Salem AK
J Control Release; 2015 Dec; 220(Pt B):682-90. PubMed ID: 26359124
[TBL] [Abstract][Full Text] [Related]
5. Time course study of the antigen-specific immune response to a PLGA microparticle vaccine formulation.
Wang Q; Tan MT; Keegan BP; Barry MA; Heffernan MJ
Biomaterials; 2014 Sep; 35(29):8385-93. PubMed ID: 24986256
[TBL] [Abstract][Full Text] [Related]
6. Innovative strategies for co-delivering antigens and CpG oligonucleotides.
Krishnamachari Y; Salem AK
Adv Drug Deliv Rev; 2009 Mar; 61(3):205-17. PubMed ID: 19272328
[TBL] [Abstract][Full Text] [Related]
7. Co-encapsulated CpG oligodeoxynucleotides and ovalbumin in PLGA microparticles; an in vitro and in vivo study.
San Román B; Gómez S; Irache JM; Espuelas S
J Pharm Pharm Sci; 2014; 17(4):541-53. PubMed ID: 25579433
[TBL] [Abstract][Full Text] [Related]
8. Induction of a balanced Th1/Th2 immune responses by co-delivery of PLGA/ovalbumin nanospheres and CpG ODNs/PEI-SWCNT nanoparticles as TLR9 agonist in BALB/c mice.
Ebrahimian M; Hashemi M; Maleki M; Abnous K; Hashemitabar G; Ramezani M; Haghparast A
Int J Pharm; 2016 Dec; 515(1-2):708-720. PubMed ID: 27989827
[TBL] [Abstract][Full Text] [Related]
9. Self-assembling CpG DNA nanoparticles for efficient antigen delivery and immunostimulation.
Rattanakiat S; Nishikawa M; Takakura Y
Eur J Pharm Sci; 2012 Sep; 47(2):352-8. PubMed ID: 22771546
[TBL] [Abstract][Full Text] [Related]
10. A protective allergy vaccine based on CpG- and protamine-containing PLGA microparticles.
Martínez Gómez JM; Fischer S; Csaba N; Kündig TM; Merkle HP; Gander B; Johansen P
Pharm Res; 2007 Oct; 24(10):1927-35. PubMed ID: 17541735
[TBL] [Abstract][Full Text] [Related]
11. Concomitant delivery of a CTL-restricted peptide antigen and CpG ODN by PLGA microparticles induces cellular immune response.
Fischer S; Schlosser E; Mueller M; Csaba N; Merkle HP; Groettrup M; Gander B
J Drug Target; 2009 Sep; 17(8):652-61. PubMed ID: 19622019
[TBL] [Abstract][Full Text] [Related]
12. Biodegradable nanoparticles containing TLR3 or TLR9 agonists together with antigen enhance MHC-restricted presentation of the antigen.
Lee YR; Lee YH; Im SA; Yang IH; Ahn GW; Kim K; Lee CK
Arch Pharm Res; 2010 Nov; 33(11):1859-66. PubMed ID: 21116790
[TBL] [Abstract][Full Text] [Related]
13. Immunological responses after immunisation of mice with microparticles containing antigen and single stranded RNA (polyuridylic acid).
Westwood A; Elvin SJ; Healey GD; Williamson ED; Eyles JE
Vaccine; 2006 Mar; 24(11):1736-43. PubMed ID: 16278038
[TBL] [Abstract][Full Text] [Related]
14. Dose sparing of CpG oligodeoxynucleotide vaccine adjuvants by nanoparticle delivery.
Diwan M; Elamanchili P; Cao M; Samuel J
Curr Drug Deliv; 2004 Oct; 1(4):405-12. PubMed ID: 16305402
[TBL] [Abstract][Full Text] [Related]
15. Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses.
Diwan M; Elamanchili P; Lane H; Gainer A; Samuel J
J Drug Target; 2003; 11(8-10):495-507. PubMed ID: 15203918
[TBL] [Abstract][Full Text] [Related]
16. Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems.
Mohanan D; Slütter B; Henriksen-Lacey M; Jiskoot W; Bouwstra JA; Perrie Y; Kündig TM; Gander B; Johansen P
J Control Release; 2010 Nov; 147(3):342-9. PubMed ID: 20727926
[TBL] [Abstract][Full Text] [Related]
17. pH-Responsive Poly(D,L-lactic-co-glycolic acid) Nanoparticles with Rapid Antigen Release Behavior Promote Immune Response.
Liu Q; Chen X; Jia J; Zhang W; Yang T; Wang L; Ma G
ACS Nano; 2015 May; 9(5):4925-38. PubMed ID: 25898266
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant activity of CpG-ODN formulated as a liquid crystal.
Sánchez Vallecillo MF; Ullio Gamboa GV; Palma SD; Harman MF; Chiodetti AL; Morón G; Allemandi DA; Pistoresi-Palencia MC; Maletto BA
Biomaterials; 2014 Mar; 35(8):2529-42. PubMed ID: 24382332
[TBL] [Abstract][Full Text] [Related]
19. [Impact of different adjuvants on immunogenicity of the HBV particle vaccine containing the S + preS1 fusion antigen in Balb/C mice].
Chen H; Deng Y; Tan W; Wang W; Yin X; Guan J; Wang W; Ruan L
Sheng Wu Gong Cheng Xue Bao; 2010 Jan; 26(1):74-8. PubMed ID: 20353095
[TBL] [Abstract][Full Text] [Related]
20. Rational design of nanoparticles towards targeting antigen-presenting cells and improved T cell priming.
Zupančič E; Curato C; Paisana M; Rodrigues C; Porat Z; Viana AS; Afonso CAM; Pinto J; Gaspar R; Moreira JN; Satchi-Fainaro R; Jung S; Florindo HF
J Control Release; 2017 Jul; 258():182-195. PubMed ID: 28511928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
